Advantage Alpha Capital Partners LP Has $1.75 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Advantage Alpha Capital Partners LP decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 43.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 87,391 shares of the biotechnology company's stock after selling 66,160 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in ADMA Biologics were worth $1,747,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. USA Financial Formulas increased its stake in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the period. Vontobel Holding Ltd. grew its holdings in ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock worth $273,000 after buying an additional 888 shares in the last quarter. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the 3rd quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. raised its stake in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after acquiring an additional 1,509 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new position in ADMA Biologics during the 3rd quarter worth $31,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of the firm's stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 185,011 shares of company stock worth $3,255,204. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on ADMA. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Cantor Fitzgerald restated an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Trading Up 1.6 %

Shares of NASDAQ ADMA traded up $0.35 during mid-day trading on Tuesday, hitting $21.82. 1,832,076 shares of the company traded hands, compared to its average volume of 3,627,180. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.04 and a beta of 0.64. The business has a 50 day moving average of $18.92 and a two-hundred day moving average of $15.05.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter in the previous year, the business earned $0.01 earnings per share. On average, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.